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Determination of the etiology of bacterial meningitis 
and estimating cost of disease are important in guiding vac-
cination policies. To determine the incidence and etiology of 
meningitis in Turkey, cerebrospinal ﬂ  uid (CSF) samples were 
obtained prospectively from children (1 month–17 years of 
age) with a clinical diagnosis of acute bacterial meningitis. 
Multiplex PCR was used to detect DNA evidence of Strepto-
coccus pneumoniae, Haemophilus inﬂ  uenzae type b (Hib), 
and Neisseria meningitidis. In total, 408 CSF samples were 
collected, and bacterial etiology was determined in 243 cas-
es; N. meningitidis was detected in 56.5%, S. pneumoniae 
in 22.5%, and Hib in 20.5% of the PCR-positive samples. 
Among  N. meningitidis–positive CSF samples, 42.7%, 
31.1%, 2.2%, and 0.7% belonged to serogroups W-135, B, 
Y, and A, respectively. This study highlights the emergence 
of serogroup W-135 disease in Turkey and concludes that 
vaccines to prevent meningococcal disease in this region 
must provide reliable protection against this serogroup.
A
cute bacterial meningitis is one of the most severe 
infectious diseases, causing neurologic sequelae and 
accounting for an estimated 171,000 deaths worldwide per 
year (1,2). Although most disease occurs in infants, the 
societal impact is also important because of the continued 
high incidence in healthy older children and adolescents. 
Despite many new antibacterial agents, bacterial meningi-
tis fatality rates remain high, with reported rates between 
2% and 30% (3,4). Furthermore, permanent sequelae, such 
as epilepsy, mental retardation, or sensorineural deafness 
are observed in 10%–20% of those who survive (5,6).
The 3 most common etiologic agents are Haemophilus 
inﬂ  uenzae type b (Hib), Streptococcus pneumoniae, and 
Neisseria meningitidis, which account for 90% of reported 
cases of acute bacterial meningitis in infants and children 
>4 weeks of age (7,8). Hib meningitis is a disease affect-
ing primarily young children; most of the cases occur in 
children 1 month to 3 years of age (3,8). The use of Hib 
conjugate vaccines has reduced the incidence of, or even 
virtually eliminated, invasive Hib disease in some indus-
trialized countries (7,8). S. pneumoniae is a major cause 
of childhood bacterial meningitis in countries where Hib 
disease has been eliminated by vaccination (9). It is the sec-
ond most frequently reported cause of septic meningitis in 
some European and sub-Saharan African countries, after 
meningococcal cases (4,9).
N. meningitidis is now considered to be the leading 
cause of bacterial meningitis in many regions of the world, 
causing an estimated 1.2 million cases of bacterial menin-
gitis and sepsis worldwide each year (10,11). Meningococ-
ci are classiﬁ  ed into 13 serogroups based on the antigenic 
properties of their capsular polysaccharide; however, near-
ly all disease is caused by 5 serogroups: A, B, C, W-135, 
and Y. The epidemiology of N. meningitidis varies by sero-
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group; currently, serogroups A, B, and C account for >90% 
of meningococcal disease worldwide (12). However, the 
epidemiologic landscape is constantly changing, and with 
increasing international travel and cross-border migration, 
the epidemiology of this disease will remain dynamic. Cur-
rently, serogroups A and C predominate throughout Asia 
and Africa, whereas serogroups B and C are responsible 
for most cases in Europe and North America (11,13–18). In 
several countries, including the United States, the propor-
tion of disease caused by serogroup Y has increased over 
the past decade, where it now accounts for approximately 
one third of meningococcal cases (19). Serogroup W-135 
has also recently emerged in some parts of the world, pri-
marily in the Middle East and Africa, in some instances 
causing large epidemics (20).
The annual Hajj pilgrimage to Mecca is a major inter-
national event; ≈2 million people from around the world 
gather in one place, where the extreme crowding provides 
an ideal environment for transmission of meningococ-
cal carriage. On several occasions, meningococcal dis-
ease outbreaks have subsequently spread worldwide by 
returning pilgrims. A major serogroup A meningococcal 
disease epidemic occurred in the 1980s, affecting Mus-
lim pilgrims initially, followed by populations in other 
Middle Eastern and African countries (21). After this 
epidemic, Hajj pilgrims were vaccinated with a bivalent 
(A and C) meningococcal polysaccharide vaccine before 
entering Saudi Arabia. With the emergence of serogroup 
W-135 meningococcal disease among Hajj pilgrims in the 
Middle East during 2000 and 2001 (20), vaccine recom-
mendations for pilgrims were changed to quadrivalent (A, 
C, W-135, and Y) meningococcal polysaccharide vaccine 
in 2002 (22).
Global surveillance of conﬁ  rmed meningococcal cases, 
including surveillance of the diversity of causative strains, 
is essential to managing disease and developing vaccines. 
This study was undertaken to determine the current etiol-
ogy of bacterial meningitis in Turkey, with particular em-
phasis on serogroup distribution of meningococci. Turkey 
is a predominantly Muslim country, and as such epidemics 
originating at the Hajj may have an effect on the national 
epidemiology. Although limited epidemiologic studies 
are available, cases of invasive meningococcal disease as 
well as carriage of serogroup W-135 have been reported in 
Turkey (23–25). This ﬁ  nding is in contrast to Western Eu-
rope, where the incidence of W-135 disease remains low. 
Turkey has no surveillance system for bacterial meningitis, 
and exact rates of meningococcal disease and serogroup 
distribution are unknown. Reliable surveillance data from 
countries such as Turkey are vital to understand, and better 
anticipate, the constantly changing landscape of bacterial 
meningitis and meningococcal disease.
Materials and Methods
Study Design
From February 16, 2005, through February 15, 2006, 
active surveillance of acute bacterial meningitis among 
children admitted to 12 participating hospitals was un-
dertaken. Turkey is divided into 7 geographic areas 
(Figure 1). Twelve health centers in 9 cities located in all 
of these 7 geographic regions were selected to represent the 
population characteristics of the country. Two centers from 
each of the 3 biggest cities and 1 center from each of the 
other cities were included. Each health center served as a 
referral center for its region in the ﬁ  eld of pediatric diseases. 
The centers serve ≈32% of the entire pediatric population 
of Turkey. Approval was obtained from the ethical com-
mittees of the participating centers and Ministry of Health.
In each hospital, suspected cases of acute bacterial 
meningitis were identiﬁ   ed by a pediatrician, based on 
the following criteria: any sign of meningitis (fever [ax-
illary measurement >38°C], vomiting [>3 episodes in 24 
h], headache, meningeal irritation signs [bulging fontanel, 
Kernig or Brudzinski signs, or neck stiffness]) in children 
>1 year of age; fever without any documented source; 
impaired consciousness (Blantyre Coma Scale <4 if 
<9 months of age and <5 if >9 months of age) (26); pros-
tration (inability to sit unassisted if >9 months of age or 
breastfeed if <9 months of age) in those <1 year of age; 
and seizures (other than those regarded as simple febrile 
seizures with full recovery within 1 h). For each suspected 
case, demographic data, predominant clinical signs and 
symptoms, prior history of use of antimicrobial agent, and 
laboratory results were recorded by using a standardized 
case report form.
Cerebrospinal ﬂ  uid (CSF) samples were obtained from 
all patients <17 years of age with clinical suspected men-
ingitis. Patient samples were included in further analyses 
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Figure 1. Meningitis cases by geographic region of Turkey. The 
number of suspected meningitis cases included in the study per 
region is shown in boldface, with the region-speciﬁ  c  estimated 
incidence rate of laboratory-conﬁ   rmed meningitis (per 100,000 
population) shown in parentheses. In total, 408 children were 
diagnosed with suspected acute bacterial meningitis. Bacterial 
meningitis was conﬁ  rmed by PCR, culture, or latex agglutination 
test in 243 cases. Region-speciﬁ  c incidence rates ranged from 1.0 
to 10.9/100,000 population. Bacterial Meningitis, Turkey
if the CSF had 1) >10 leukocytes/mm3 in the CSF, and/or 
2) higher CSF protein levels than normal for the patient’s 
age, and/or 3) lower CSF glucose levels than normal for 
the patient’s age. In addition to these patients, all who had 
a positive CSF culture, PCR, Gram stain, or antigen detec-
tion test result were also included in the study. No neo-
nates (<1 month of age) were included in the study since 
the pathogens of neonatal meningitis were expected to be 
different than those of the older case-patients (3).
CSF Cultures and Bacterial Isolates
CSF cultures, Gram stain, and latex agglutination 
tests (Wellcogen Bacterial Antigen Kit, Lenexa, KS, 
USA) were performed in the local hospitals. A CSF 
sample (minimum 0.5 mL) from each patient was kept at 
–20°C until transportation to the Central Laboratory (Hac-
ettepe University, Ankara, Turkey) for PCR analysis. CSF 
samples and, if available, bacterial isolates were sent to 
the Central Laboratory, where all isolates were recultured 
on chocolate and blood agars and grown at 37°C in 5% 
CO2. Suspected meningococcal colonies were character-
ized by Gram stain, oxidase test, and rapid carbohydrate 
utilization test (Gallerie Pasteur, Pasteur Merieux, Lyon, 
France). The microbiology laboratory records were cross-
checked in each hospital for missing data. The phenotypic 
determination, based on the antigenic formula (serogroup:
serotype:serosubtype) of meningococcal isolates, was 
performed by standard methods in the Meningococcal 
Reference Unit, Health Protection Agency, Manchester, 
United Kingdom (18,20–25,27).
DNA Isolation
All samples collected in the Central Laboratory were 
kept at –80°C and were thawed immediately before each 
test. Bacterial colonies were suspended in 500 μL sterile 
double-distilled water and vortexed. Bacterial suspen-
sions and CSF were boiled for 3 min at 100°C, then cen-
trifuged for 5 min at 10,000 × g, and the supernatant was 
retained. DNA concentration was estimated spectropho-
tometrically, and 15 μL (≈50 ng) was used in each ﬁ  nal 
reaction mixture.
PCR Ampliﬁ  cation
For the simultaneous identiﬁ   cation of bacterial 
agents, single tube, multiplex PCR assay was performed. 
The speciﬁ  c gene targets were ctrA, bex, and ply for N. 
meningitidis, Hib, and S. pneumoniae, respectively (28). 
In each assay, the ﬁ  nal reaction mixture of 50 μL con-
tained 15 μL (≈50 ng) DNA, 1× PCR buffer, 3 mmol/L 
MgCl2, 200 μmol/L of each dNTP (AB Gene, Epsom, 
UK), 0.6 μmol/L of each corresponding oligonucleotide 
primer (Sigma Aldrich, Seezle, Germany) as described 
(28) and 1 U of Taq polymerase (AB Gene). The PCR was 
performed by using a DNA thermal cycler (Perkin-Elmer 
Cetus, Emeryville, CA, USA model 9600) under the fol-
lowing conditions: a ﬁ  rst cycle of denaturation at 95°C for 
5 min followed by 35 cycles of 95°C for 25 s, 57°C for 40 
s, and 72°C for 60 s.
Among the samples positive for N. meningitidis, se-
rogroup prediction (A, B, C, W-135, and Y) was based on 
the oligonucleotides in the siaD gene for serogroups B, C, 
W-135, and Y and in orf-2 of a gene cassette required for 
serogroup A (28). For serogroup determination, ampliﬁ  ca-
tion reactions (50 μL) contained 15 μL of DNA, 60 mmol/L 
Tris-HCl (pH 8.8), 17 mmol/L (NH4)2SO4, 5 mmol/L Mg-
Cl2, 0.5 mmol/L of each dNTP, 0.3 μmol/L corresponding 
oligonucleotides, and 1 U of Taq polymerase. The PCR 
conditions were as follows: denaturation at 94°C for 3 min, 
followed by 35 cycles of 92°C for 40 s, 55°C for 30 s, and 
72°C for 20 s in a DNA thermal cycler. A ﬁ  nal extension 
cycle at 72°C for 10 min was then performed (29).
All amplicons were analyzed by electrophoresis on 
standard 3% agarose gels and visualized by using UV ﬂ  uo-
rescence. A negative control consisting of distilled water and 
a positive control consisting of a reference strain (S. pneu-
moniae ATCC 49613, Hib ATCC 10211, N. meningitidis 
serogroup C L94 5016 also known as C11 [C:16:P1.7–1,1], 
serogroup A M99 243594 [A:4,21:P1.20,9], serogroup Y 
M05 240122 [Y:NT:P1.5], serogroup W135 M05 240125 
[W135:2a:NST], serogroup B M05 240120 [B:NT:NST]) 
were analyzed simultaneously.
Statistical Analysis
Continuous variables were compared by the Student t 
test and categorical variables with χ2 or Fisher exact tests. 
A 2-tailed p value <0.05 was considered signiﬁ  cant. All 
statistical analysis was performed with SPSS version 11.5 
(SPSS Inc, Chicago, IL, USA).
Results
Meningitis Cases
In total, 408 children were hospitalized with a clini-
cal diagnosis of meningitis during the study period (Fig-
ure 1), and a CSF sample from each patient was obtained. 
The distribution of these suspected cases according to the 
geographic regions was as follows: 109 (26.7%) in South-
ern Anatolia, 74 (18.1%) in Aegean region, 79 (19.6%) 
in Central Anatolia, 53 (13.0%) in Marmara region, 43 
(8.7%) in Eastern Anatolia, 24 (5.9%) in Black Sea re-
gion, and 26 (6.4%) in Mediterranean region. The mean 
age of the 408 children was 4.8 years (standard devia-
tion 4.1 years), and the boy-to-girl ratio was 1.5:1. Of 408 
patients diagnosed with acute bacterial meningitis, 20 
(4.9%) died and 14 (5.7%) of these deaths were among 
patients with laboratory-conﬁ  rmed cases.
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 7, July 2008  1091 RESEARCH
Laboratory-Conﬁ  rmed Meningitis Cases and Etiology
Of the 408 cases, bacterial meningitis was conﬁ  rmed 
by PCR, culture, or latex agglutination test in 243 (59.6%) 
patients. Regional incidence rates of laboratory-conﬁ  rmed 
meningitis were estimated as ranging from 1/100,000 popu-
lation in the Black Sea region to 10.9/100,000 population in 
the Southeast Anatolia region (Figure 1). Nationwide, the 
highest incidence was in children 1–12 months of age and 
was slightly more common in boys. The boy-to-girl ratio of 
the conﬁ  rmed cases was 1.3:1, and the age distribution was 
as shown in Figure 2.
Overall, the diagnosis of acute bacterial meningitis 
was conﬁ  rmed with CSF culture in 41 (17%) of 243 cases, 
with latex agglutination test in 56 (23%), and with PCR in 
243 (100%) (Table). Latex agglutination test was positive 
in 37 cases for N. meningitidis, in 10 cases for Hib, and in 
9 cases for S. pneumoniae.
Where data were available, 7 (17%) of 41 cases with 
positive CSF culture and 111 (54.9%) of 202 cases with 
negative CSF culture had a history of use of antimicrobial 
agent(s) before lumbar puncture, which may account for 
the relatively low diagnosis rate by using this technique. N. 
meningitidis was reported in 23 cases, S. pneumoniae was 
reported in 12, and Hib was reported in 6 cases as positive 
in CSF culture.
Blood culture was positive in 12 (4.9%) of 243 cas-
es—4 each of N. meningitidis, Hib, and S. pneumoniae. Phe-
notyping of 21 available isolates indicated W135:2a:P1.5,2 
(5 cases), A:21:NT:P1.10 (1 case), B:NT:P1.12,4 (2 
cases), B:22:NT:NT (2 cases), B:NT:NT:P1.14 (2 cas-
es), B:15:P1.7,16 (3 cases), B:14:NT:P1.13 (2 cases), 
B:15:NT:P1.16 (2 cases), X:NT:P1.7,1 (1 case), Y: 
NT:P1.5:NT (1 case).
PCR analysis was by far the most reliable method of 
conﬁ   rming bacterial meningitis, accounting for all con-
ﬁ  rmed cases with 243 positive results. In these PCR-pos-
itive samples, 138 (56.5%) were attributable to N. menin-
gitidis, 55 (22.5%) to S. pneumoniae, and 50 (20.5%) to 
Hib (Figure 3). Of the 408 patients, 118 (48.5%) of 243 
cases with positive PCR and 96 (58.2%) of 165 cases with 
negative PCR had received antibacterial drugs in the week 
before CSF sampling.
In the evaluation of the bacterial agents among the 7 
different geographic regions of the country, N. meningitidis 
was the most common cause of acute bacterial meningitis 
in all regions except the Mediterranean region, located on 
the southern coast of Turkey. Here S. pneumoniae were the 
prominent bacteria, and N. meningitidis were detected in 
only 2 cases.
Comparison of the incidence of N. meningitidis,  S. 
pneumoniae, and Hib among different age groups dem-
onstrated that N. meningitidis was the prominent bacterial 
agent causing acute bacterial meningitis, especially in chil-
dren <7 years of age (Figure 2). The highest incidence was 
detected during the ﬁ  rst year of life for all 3 bacteria.
CSF ﬁ  ndings were recorded for 368 (90.2%) of 408 
CSF samples sent to the Central Laboratory. As a mean, in 
PCR-negative samples, CSF protein level was signiﬁ  cantly 
lower (70.2 vs. 130.4 mg/dL; p = 0.003) and glucose level 
was signiﬁ  cantly higher (55.6 vs. 41.3 mg/dL; p = 0.01) than 
in PCR-positive samples. Total cell counts were not sig-
niﬁ  cantly different in PCR-negative and -positive samples 
(157.9 and 211.1/mm3; p>0.05), but polymorphonuclear 
cell count was signiﬁ  cantly higher in PCR-positive samples 
(8,284.3 vs. 38.5/mm3; p = 0.001). Among the PCR-positive 
samples, total cell and polymorphonuclear cell counts were 
not signiﬁ  cantly different between samples positive for N. 
meningitidis, S. pneumoniae, and Hib (p>0.05).
Meningococcal Epidemiology
Among the samples that were positive for N. menin-
gitidis following PCR analysis, serogroup W-135 was the 
cause of most infections; 59 (42.7%) cases were serogroup 
W-135, 43 (31.1%) were serogroup B, 3 (2.2%) were se-
rogroup Y, and 1 (0.7%) was serogroup A. There were no 
cases with a positive result for serogroup C (this was also 
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Table. Laboratory confirmation of bacterial meningitis* 
Category 
PCR positive 
(n = 243) 
PCR negative 
(n = 165) 
Total 
(n = 408) 
CSF culture 
 Positive  41 0 41
 Negative  202 165 367
Latex agglutination test 
 Positive  53 3 56
 Negative  190 162 352
*Specimens positive for individual assays and combinations of assays. 
CSF, cerebrospinal fluid. 
Figure 2. Distribution of bacteria causing childhood acute bacterial 
meningitis in different age groups. Neisseria meningitidis was the 
most common cause of meningitis, and the highest estimated 
incidence was in children <1 year of age for all 3 bacteria. The 
number of cases is indicated above each bar. S. pneumoniae, 
Streptococcus pneumoniae; Hib, Haemophilus inﬂ  uenzae type b.Bacterial Meningitis, Turkey
the case following analysis of CSF culture-positive sam-
ples) and in 32 (23.2%) N. meningitidis–positive samples 
the serogroup could not be determined by the PCR assay.
Analysis by age reveals the greatest meningococcal 
disease incidence is in children <3 years of age, particu-
larly infants <1 year of age. The numbers of cases caused 
by the 2 most common N. meningitidis serogroups (sero-
groups W-135 and B) were similar in the most vulnerable 
age groups (<3 years of age), but W-135 was more com-
mon in children 4–16 years of age (Figure 4).
Etiologic and meningococcal serogroup distribu-
tion among the different geographic regions is illustrated 
in Figure 5. N. meningitidis serogroup W-135 was more 
prominent than the other meningococcal serogroups in the 
Southeast Anatolia, Aegean (Western Turkey), Eastern 
Anatolia, and Black Sea regions. N. meningitidis serogroup 
B was much more common in the Marmara region (north-
western Turkey), and in the Central region; the numbers 
of serogroup B and serogroup W-135 cases were similar. 
The Mediterranean region had 2 N. meningitidis–positive 
samples; both were nongroupable by PCR analysis.
Discussion
In this study, 243 cases of laboratory-conﬁ  rmed acute 
bacterial meningitis were recorded. Because our study cen-
ters provide service to 32% of the population of Turkey, ex-
trapolation from the number of cases recorded suggests that 
759 acute bacterial meningitis cases (excluding neonatal 
cases) per year occur in the whole country. The population 
of children 1 month through 16 years of age was calculated 
as 21.6 million. Therefore, the annual incidence of acute 
bacterial meningitis was estimated as 3.5 cases/100,000/
year. Although similar to incidence rates reported from 
other countries without routine vaccination against N. men-
ingitidis, S. pneumoniae, and Hib (3,4,10,30), this value 
likely represents a lower limit estimate of the true disease 
incidence, given the inherent limitations of hospital-based 
surveillance. Furthermore, the speciﬁ  c role of these 3 most 
common bacterial causes of acute bacterial meningitis var-
ies between regions.
An accurate laboratory conﬁ  rmation of the etiology in 
acute bacterial meningitis is essential to provide optimal 
patient therapy, appropriate case contact management, and 
reasoned public health actions. Prospectively, it also pro-
vides information upon which to base decisions regarding 
immunization programs, especially for countries without 
routine vaccination against the main acute bacterial men-
ingitis pathogens (28,31). Although bacterial culture is 
considered to be the standard method, the negative effect 
of prior antimicrobial drug use on its sensitivity necessi-
tates nonculture techniques for diagnosis. Among noncul-
ture diagnostic tests, PCR is the most accurate and reliable 
method, especially among patients with a history of anti-
microbial drug use before spinal tap (32). This ﬁ  nding was 
evident in the present study, in which PCR analysis was 
the most sensitive method, conﬁ  rming 243 cases (59.6%) 
among 408 children meeting the case deﬁ  nition for bacte-
rial meningitis (100% of all cases that were conﬁ  rmed by 
any method). Using other methods that are more sensitive 
may increase the rate of laboratory conﬁ  rmation.
Several reports review the rates of bacterial causes of 
acute bacterial meningitis from many different countries, 
based on CSF cultures. Some factors, such as previous an-
timicrobial drug treatment, interfere with the recovery of 
microorganisms from CSF. In our study, bacterial isolation 
was only possible in 41(16.8%) of 243 of conﬁ  rmed cases. 
However, the most important factor for this low positive 
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Figure 3. Distribution of etiology of acute bacterial meningitis in 
Turkey detected by using PCR analysis. Of 243 PCR-conﬁ  rmed 
cases, 138 (56.5%) were attributable to Neisseria meningitidis, 
55 (22.5%) to Streptococcus pneumoniae, and 50 (20.5%) to 
Haemophilus inﬂ  uenzae type b (Hib). 
Figure 4. Distribution of predominant Neisseria meningitidis 
serogroups in different age groups. Serogroups W-135 and B caused 
42.7% and 31.1% of all meningococcal infections, respectively. 
W-135 was the most common cause of meningococcal infection in 
all but 2 age groups analyzed.RESEARCH
ratio in culture was likely prior antimicrobial drug use, as 
118 case-patients received such treatment before the lum-
bar puncture (7/41; 17% in culture-positive case-patients 
and 111 (54.9%) of 202 in culture-negative case-patients). 
In patients with acute bacterial meningitis, blood cultures 
can be used in the etiologic diagnosis in up to 80% of cases 
since the bacteria generally invade meningeal membranes 
following bacteremia (3,10,33). In our study, however, 
only 12 (4.9%) of 243 case-patients who had blood culture 
tests returned positive results. This ﬁ  nding may also be re-
lated to the previous antimicrobial drug use.
Previous reports suggested that S. pneumoniae and N. 
meningitidis serogroups A and B would be the most com-
mon bacteria causing acute bacterial meningitis in Tur-
key (25,34–36). Serogroup W-135 meningococcus was 
isolated for the ﬁ  rst time in Turkey in an asymptomatic 
healthy preschool child in 2001 (23), and the ﬁ  rst patient 
with meningitis caused by serogroup W-135 was reported 
in 2003 (24). In this study N. meningitidis, especially se-
rogroup W-135, was responsible for most of the cases ob-
served, with serogroup B the second most common. Only 
a small number of serogroup A or Y cases were noted, 
and no serogroup C cases were observed. These data are 
in contrast to those from many parts of Europe, where se-
rogroups B and C dominate the epidemiologic landscape. 
In Turkey, meningococcal disease caused by serogroup 
W-135 has increased from 1 case in 2003 to 59 cases or 
42.7% of all laboratory-conﬁ  rmed N. meningitidis cases 
in children, in this study, during 2005/06. A dramatic in-
crease in serogroup Y disease has been documented in 
the United States during the last decade, but this has been 
over a longer period.
Most of the Turkish population is Muslim, and 
≈150,000 pilgrims travel annually to Saudi Arabia for the 
Hajj. Since 2002, all Turkish pilgrims have received a qua-
drivalent meningococcal polysaccharide vaccine before 
travel. Although this vaccine generates a robust immune 
response against serogroup W-135, in contrast to what has 
been demonstrated for serogroup C meningococcal conju-
gate vaccines (37), meningococcal polysaccharide vaccines 
are not thought to reliably prevent asymptomatic carriage. 
A study from the United States reported that 0.8% of re-
turning vaccinated pilgrims in 2001 were carrying W-135, 
whereas no pilgrims carried this serogroup upon departure 
from the United States (38). Therefore, the rapid rise in the 
proportion of cases caused by serogroup W-135 may be 
attributable to transmission from pilgrims returning from 
the Hajj carrying this particular serogroup. Although not 
deﬁ  nitive, this conclusion is further supported by the ﬁ  nd-
ing that all serogroup W-135 isolates available for pheno-
typic characterization were identical to the Hajj-associated 
clone, W135:2a:P1.5,2 (20). Because strains with this se-
rologic proﬁ  le have not been uniquely associated with the 
Hajj outbreak (39), additional typing data (e.g., multilocus 
sequence typing or multilocus enzyme electrophoresis), 
and epidemiologic investigations will be required to sup-
port this hypothesis. Therefore, it remains speculative that 
the increased W-135 disease in Turkey may be caused by 
spread of Hajj epidemic strain through carriage and trans-
mission by pilgrims.
This study demonstrates the need for good quality, 
continued surveillance of bacterial meningitis cases, as well 
as the etiology and epidemiology of the causative bacteria. 
Only by accurately monitoring meningococcal epidemiol-
ogy will effective vaccination policies be developed. The 
bacterial meningitis epidemiologic landscape is not static, 
and the causative agents change with time and across re-
gions of the world. This study has demonstrated that the 
relative contribution of serogroup W-135 to the meningo-
coccal disease incidence in Turkey is increasing, which is 
in contrast to the rest of Europe. Turkey may remain isolat-
ed in terms of W-135 disease incidence or it may represent 
the beginning of epidemiologic change in Eastern Europe. 
This possibility should be investigated in greater depth and 
monitored prospectively. Introduction of vaccines can dra-
matically reduce the meningitis disease incidence, but these 
vaccines must be targeted against the correct bacteria and, 
where relevant, the correct bacterial serogroup. The choice 
of meningococcal conjugate vaccines in Turkey will need 
to include coverage for serogroup W-135; introduction of 
such a vaccine would be helpful in protecting the Turkish 
population from this invasive bacterial meningitis. More-
over, it may also be prudent to switch the meningococcal 
vaccine used for pilgrims to conjugated vaccine to prevent 
the carriage of the microorganism by pilgrims.
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Figure 5. Etiology of conﬁ   rmed cases of bacterial meningitis in 
different geographic regions. W-135 was the most prominent 
Neisseria meningitidis serogroup in the Southeast Anatolia, 
Aegean, Eastern Anatolia, and Black Sea regions. The percentages 
of cases caused by Streptococcus pneumoniae and Haemophilus 
inﬂ  uenzae type b (Hib) are also shown. Bacterial Meningitis, Turkey
include vaccines, epidemiology of vaccine-preventable diseases, 
and mechanisms of antibacterial resistance.
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